{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:53:50Z","timestamp":1794002030287,"version":"4.8.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The antiapoptotic protein, myeloid cell leukemia-1 (Mcl-1), contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models. This dose escalation study evaluated voruciclib in patients with previously treated hematologic malignancies. Initially, voruciclib was administered daily, continuously, on a 28-day cycle (group 1). After 2 patients with prior allogeneic stem cell transplantation had a dose-limiting toxicity (DLT) of interstitial pneumonitis at 100\u00a0mg, voruciclib administration was changed to days 1 to 14 of a 28-day cycle (group 2). Forty patients, 21 with AML and 19 with B-cell malignancies, were enrolled. Patients had a median of 3 prior lines of therapy (range, 1-8). Dose escalation in group 2 was stopped at 200\u00a0mg, a dose that achieved plasma concentrations sufficient for target inhibition, without DLTs observed. The most common adverse events were diarrhea (30%), nausea (25%), anemia (22%), fatigue (22%), constipation (17%), dizziness (15%), and dyspnea (15%). In AML, 1 patient achieved a morphologic leukemia-free state, and 2 had stable disease. Voruciclib treatment led to a decrease in MCL1 messenger RNA expression, downregulation of myelocytomatosis (MYC) and NF-\u03baB transcriptional gene sets, and reduced phosphorylation of RNA polymerase 2. Voruciclib on intermittent dosing was well tolerated, with no DLTs, paving the way for evaluation of the combination of voruciclib with venetoclax for patients with previously treated AML. This trial was registered at www.clinicaltrials.gov as #NCT03547115.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014633","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:00:44Z","timestamp":1734706844000},"page":"820-832","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["A phase 1 study of the CDK9 inhibitor voruciclib in relapsed\/refractory acute myeloid leukemia and B-cell malignancies"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2003","authenticated-orcid":false,"given":"Matthew S.","family":"Davids","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9581-2807","authenticated-orcid":false,"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7937","authenticated-orcid":false,"given":"Yesid","family":"Alvarado-Valero","sequence":"additional","affiliation":[{"name":"3Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1116-3246","authenticated-orcid":false,"given":"Catherine S.","family":"Diefenbach","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Division of Hematology and Medical Oncology, New York University Langone Perlmutter Cancer Institute, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-1188","authenticated-orcid":false,"given":"Daniel N.","family":"Egan","sequence":"additional","affiliation":[{"name":"5Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-6741","authenticated-orcid":false,"given":"Shira N.","family":"Dinner","sequence":"additional","affiliation":[{"name":"6Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0702-9837","authenticated-orcid":false,"given":"Nathalie","family":"Javidi-Sharifi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[{"name":"7Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2730-8593","authenticated-orcid":false,"given":"Kebede H.","family":"Begna","sequence":"additional","affiliation":[{"name":"8Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-0533","authenticated-orcid":false,"given":"Vijaya Raj","family":"Bhatt","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Division of Oncology & Hematology, The Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[{"name":"10Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7005-036X","authenticated-orcid":false,"given":"Rachel J.","family":"Cook","sequence":"additional","affiliation":[{"name":"11Center for Hematologic Malignancies, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4282-9020","authenticated-orcid":false,"given":"Mary C.","family":"Collins","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9844-0367","authenticated-orcid":false,"given":"Carly","family":"Roleder","sequence":"additional","affiliation":[{"name":"12Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5542-0289","authenticated-orcid":false,"given":"Edward C.","family":"Dominguez","sequence":"additional","affiliation":[{"name":"12Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-8458","authenticated-orcid":false,"given":"Prabhu","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"13PR Consulting, Mountain Lakes, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3979-2474","authenticated-orcid":false,"given":"Sandra E.","family":"Wiley","sequence":"additional","affiliation":[{"name":"14MEI Pharma, Inc, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-8179","authenticated-orcid":false,"given":"Richard G.","family":"Ghalie","sequence":"additional","affiliation":[{"name":"14MEI Pharma, Inc, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[{"name":"12Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"3","key":"2025032418272779000_bib1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2008-08-173450","article-title":"Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab","volume":"113","author":"Awan","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2025032418272779000_bib2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3324\/haematol.2020.260331","article-title":"Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition","volume":"107","author":"Carter","year":"2022","journal-title":"Haematologica"},{"issue":"20","key":"2025032418272779000_bib3","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: from cellular function and regulation to pharmacological inhibition","volume":"289","author":"Sancho","year":"2022","journal-title":"FEBS J"},{"issue":"15","key":"2025032418272779000_bib4","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1158\/0008-5472.CAN-10-4531","article-title":"Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition","volume":"71","author":"Coloff","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"2025032418272779000_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"2025032418272779000_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2014.320","article-title":"Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia","volume":"29","author":"Huelsemann","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2025032418272779000_bib49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025032418272779000_bib50","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"12","key":"2025032418272779000_bib7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"issue":"5","key":"2025032418272779000_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2025032418272779000_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/jcb.26293","article-title":"CDK9: a key player in cancer and other diseases","volume":"119","author":"Franco","year":"2018","journal-title":"J\u00a0Cell Biochem"},{"issue":"9","key":"2025032418272779000_bib10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1535-7163.MCT-18-1023","article-title":"Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma","volume":"18","author":"Hashiguchi","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"2025032418272779000_bib11","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","article-title":"Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX-dependent manner","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2025032418272779000_bib12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","article-title":"Mammalian cyclin-dependent kinases","volume":"30","author":"Malumbres","year":"2005","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"2025032418272779000_bib13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-023-01762-6","article-title":"CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma","volume":"22","author":"Thieme","year":"2023","journal-title":"Mol Cancer"},{"issue":"7","key":"2025032418272779000_bib14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2009.017103","article-title":"Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias","volume":"95","author":"Blum","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"2025032418272779000_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"6","key":"2025032418272779000_bib16","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/13543784.2013.789859","article-title":"Cyclin-dependent kinase inhibitor therapy for hematologic malignancies","volume":"22","author":"Bose","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2025032418272779000_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"6046","key":"2025032418272779000_bib51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/318533a0","article-title":"The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice","volume":"318","author":"Adams","year":"1985","journal-title":"Nature"},{"issue":"4","key":"2025032418272779000_bib52","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0092-8674(86)90280-1","article-title":"Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development","volume":"45","author":"Leder","year":"1986","journal-title":"Cell"},{"issue":"4","key":"2025032418272779000_bib53","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.semcancer.2006.07.012","article-title":"Conditional transgenic models define how MYC initiates and maintains tumorigenesis","volume":"16","author":"Arvanitis","year":"2006","journal-title":"Semin Cancer Biol"},{"issue":"6299","key":"2025032418272779000_bib54","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/348331a0","article-title":"Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2","volume":"348","author":"Strasser","year":"1990","journal-title":"Nature"},{"issue":"4","key":"2025032418272779000_bib22","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","article-title":"MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation","volume":"26","author":"Lee","year":"2017","journal-title":"Cell Metab"},{"issue":"1","key":"2025032418272779000_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2013.1.575","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"2013","author":"Ott","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"15","key":"2025032418272779000_bib19","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025032418272779000_bib55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10428194.2018.1464158","article-title":"MYC Protein Expression is an Important Prognostic Factor in Acute Myeloid Leukemia","volume":"60","author":"Ohanian","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2025032418272779000_bib20","doi-asserted-by":"crossref","first-page":"18007","DOI":"10.1038\/s41598-017-18368-w","article-title":"Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition","volume":"7","author":"Dey","year":"2017","journal-title":"Sci Rep"},{"issue":"21","key":"2025032418272779000_bib21","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood.V122.21.1636.1636","article-title":"A\u00a0novel cyclin dependent kinase inhibitor P1446A induces apoptosis of chronic lymphocytic leukemia B cells","volume":"122","author":"Godbersen","year":"2013","journal-title":"Blood"},{"issue":"suppl 15","key":"2025032418272779000_bib24","doi-asserted-by":"crossref","first-page":"e20009","DOI":"10.1200\/JCO.2020.38.15_suppl.e20009","article-title":"Voruciclib plus venetoclax show high efficacy for CLL b cells on human stromal cells","volume":"38","author":"Lesnick","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032418272779000_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-020-0112-3","article-title":"Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia","volume":"5","author":"Luedtke","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2025032418272779000_bib26","doi-asserted-by":"crossref","first-page":"e0143685","DOI":"10.1371\/journal.pone.0143685","article-title":"Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK\/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells","volume":"10","author":"Paiva","year":"2015","journal-title":"PLoS One"},{"issue":"suppl 15","key":"2025032418272779000_bib27","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/jco.2012.30.15_suppl.3011","article-title":"A\u00a0phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors","volume":"30","author":"Gupta","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"2025032418272779000_bib28","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1200\/jco.2012.30.15_suppl.3013","article-title":"A\u00a0phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor","volume":"30","author":"Hao","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2025032418272779000_bib31","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2025032418272779000_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2025032418272779000_bib33","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2025032418272779000_bib29","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025032418272779000_bib34","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"2","key":"2025032418272779000_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.seminoncol.2016.02.003","article-title":"Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia","volume":"43","author":"Blachly","year":"2016","journal-title":"Semin Oncol"},{"issue":"3","key":"2025032418272779000_bib35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2025032418272779000_bib36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/bjc.2017.288","article-title":"Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies","volume":"117","author":"Mita","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"2025032418272779000_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/15384101.2016.1138186","article-title":"Overview of CDK9 as a target in cancer research","volume":"15","author":"Morales","year":"2016","journal-title":"Cell Cycle"},{"issue":"4","key":"2025032418272779000_bib38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","article-title":"Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias","volume":"72","author":"Gojo","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2025032418272779000_bib39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2025032418272779000_bib40","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","article-title":"Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models","volume":"106","author":"Singh Mali","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2025032418272779000_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","author":"Han","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"2025032418272779000_bib42","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1080\/10428194.2023.2244102","article-title":"Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications","volume":"64","author":"Dominguez","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2025032418272779000_bib43","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2022-167203","article-title":"Safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of the cyclin-dependent kinase-9 (CDK9) inhibitor AZD4573 in relapsed\/refractory hematological malignancies: a phase 1 first-in-human study","volume":"140","author":"Brummendorf","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032418272779000_bib44","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1182\/blood-2022-165979","article-title":"Phase 1b\/2a study of AZD4573 (CDK9i) and acalabrutinib in patients with relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): results from dose-escalation","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"issue":"suppl 12","key":"2025032418272779000_bib45","article-title":"A\u00a0phase 1, open-label, dose-escalation study of a CDK9 inhibitor, PRT2527, in adult patients with advanced solid tumors: an updated analysis","volume":"22","author":"Patel","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"2025032418272779000_bib46","doi-asserted-by":"crossref","first-page":"9454","DOI":"10.1182\/blood-2022-167651","article-title":"Enitociclib (VIP152\/formerly BAY1251152) is a selective and active CDK9 inhibitor : preliminary safety and early signs of efficacy in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)","volume":"140","author":"Shadman","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032418272779000_bib47","doi-asserted-by":"crossref","first-page":"9473","DOI":"10.1182\/blood-2022-159844","article-title":"First in human (FIH) study of GFH009, a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with relapsed\/refractory (r\/r) hematologic malignancies","volume":"140","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032418272779000_bib48","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0959-8049(22)00849-8","article-title":"A\u00a0Phase 1\/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2\/9 inhibitor, in subjects with advanced solid tumors and lymphoma","volume":"174","author":"Piha-Paul","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/820\/2355959\/blooda_adv-2024-014633-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/820\/2355959\/blooda_adv-2024-014633-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T16:29:19Z","timestamp":1742833759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/820\/534793\/A-phase-1-study-of-the-CDK9-inhibitor-voruciclib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014633","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}